Evaluation of safety and efficacy of T-AYU-HM Premium and Onion steam vaporization/nebulization in Covid-19 patients.

Evaluation of safety and efficacy of T-AYU-HM Premium and Onion Steam vaporisation/nebulization in Covid-19 patients (mild to moderate)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027477

Enrollment

Registered

2020-08-31

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Tablet T-AYU-HM Premium: 600mg orally BD for 21 days. Intervention2: Onion steam vaporization/nebulisation : Nasally OD for 21 days Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years, 2. Both male and female 3. Mild to Moderate cases under home quarantine. 4. Willing to perform onion vaporization/nebulizationÃ¢â?¬Â¨ once a day 5. Patients able to consume oral formulations. 6. Willing to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Require mechanical ventilation 2. Unable to perform onion vaporization/nebulisation once a day. 3. Having serious stages illness 4. Pregnant/lactating women 5. Children below 18 years age

Design outcomes

Primary

Measure	Time frame
1. Total number of participants with improvement in clinical symptoms Ã¢â?¬â?? fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia). 2. Total number of participants with resolution of clinical symptoms fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia).Timepoint: 21 days	—

Measure

Time frame

1. Total number of participants with improvement in clinical symptoms Ã¢â?¬â?? fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia). 2. Total number of participants with resolution of clinical symptoms fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia).Timepoint: 21 days

—

Secondary

Measure	Time frame
1. Oxygen requirement of patients 2. Improvement in oxygen saturation 3. Improvement in respiratory rate 4. Improvement in haematological parameters 5. Improvement in the level of other inflammatory markers CRP, ESR, LDH Timepoint: Baseline 5th day 21th day	—

Countries

India

Contacts

Public ContactDr Hemshree Desai

Dhanvantari Clinic, Ayurveda health care and research center

dratuldesai@rediffmail.com9879031621

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026